Neuvenge
Neuvenge
Neuvenge (pronounced: noo-venj) is a type of immunotherapy used in the treatment of certain types of cancer, specifically prostate cancer. It is a form of vaccine that is designed to stimulate the body's immune system to fight against cancer cells.
Etymology
The term "Neuvenge" is a brand name and does not have a known etymology. It is a proprietary name for the drug sipuleucel-T, which is produced by the pharmaceutical company Dendreon.
Usage
Neuvenge is used in the treatment of metastatic hormone-refractory prostate cancer, a type of prostate cancer that has spread to other parts of the body and is not responding to hormone therapy. The drug works by stimulating the patient's immune system to attack the cancer cells.
Related Terms
- Immunotherapy: A type of treatment that uses the body's immune system to fight diseases such as cancer.
- Prostate Cancer: A type of cancer that occurs in the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.
- Metastatic: Refers to cancer that has spread from the place where it first started to another place in the body.
- Hormone Therapy: A cancer treatment that removes, blocks, or adds hormones to treat certain types of cancer.
- Sipuleucel-T: The generic name for Neuvenge, a type of immunotherapy used in the treatment of prostate cancer.
- Dendreon: The pharmaceutical company that produces Neuvenge.
External links
- Medical encyclopedia article on Neuvenge
- Wikipedia's article - Neuvenge
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski